Psychiatric Annals, 2011;41(3):166–175
Cite this articlePublished Online:February 24, 2011https://doi.org/10.3928/00485713-20110224-06Cited by:1
- 1.2009 Top 200 generic drugs by total prescription. Drug Topics: The Newsmagazine For Pharmacists. 20101–3. Available at: drugtopics.modernmedicine.com/drugtopics/data/articles-tandard/drugtopics/252010/674982/article.pdf. Accessed Feb. 1, 2011. > Google Scholar
- 2.Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(3):326–333.
10.4088/JCP.08m04637 > CrossrefGoogle Scholar - 3.Buspar [package insert]. Princeton, NJ. Bristol-Myers Squibb: 2010November. > Google Scholar
- 4.Stahl S. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. New York, NY: Cambridge University Press, 2000. > Google Scholar
- 5.Gammans E, Stringfellow JC, Hvizdos AJ, Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. Neuropsychobiology. 1992; 25(4):193–201.
10.1159/000118837 > CrossrefGoogle Scholar - 6.Chessik CA, Allen MH, Azapirones for generalized anxiety disorders. Cochrane Database for Systematic Reviews. 2006: Issue 3: Art No.: CD006115. CD006115. DOI:
10.1002/14651858 . > CrossrefGoogle Scholar - 7.Strand M, Hetta J, Rosen A, A double-blind controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry. 1990; 51(9 Suppl):40–45. > Google Scholar
- 8.Pecknold JC, Matas M, Howarth BG, Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry. 1989; 34(8):766–771. > Google Scholar
- 9.Cohn JB, Bowden CL, Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med. 1986; 80(3B):10–16.
10.1016/0002-9343(86)90326-8 > CrossrefGoogle Scholar - 10.Laakmann G, Schule C, Lorkowski G, Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998; 136:357–366.
10.1007/s002130050578 > CrossrefGoogle Scholar - 11.Cohn JB, Wilcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients. J Clin Psychiatry. 1986; 47(8):409–412. > Google Scholar
- 12.Schweizer E, Rickels K, Lucki I. Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. New Engl J Med. 1986; 314(11):719–720.
10.1056/NEJM198603133141121 > CrossrefGoogle Scholar - 13.DeMartinis N, Rynn M, Rickels K, Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2000; 61(2):91–94.
10.4088/JCP.v61n0203 > CrossrefGoogle Scholar - 14.Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999; 60(8):528–535.
10.4088/JCP.v60n0805 > CrossrefGoogle Scholar - 15.Enkelmann R. Alprazolam versus buspirone in the treatment of generalized anxiety disorder. Psychopharmacology (Berl). 1991; 105(3):428–432.
10.1007/BF02244440 > CrossrefGoogle Scholar - 16.Sramek JJ, Hong WW, Hamid S. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depress Anxiety. 1999; 9(3):131–134.
10.1002/(SICI)1520-6394(1999)9:3<131::AID-DA5>3.0.CO;2-H > CrossrefGoogle Scholar - 17.Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry. 1990; 51(Suppl):55–61. > Google Scholar
- 18.Robinson DS, Rickels K, Feighner J, Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacology. 1990; 10(Suppl 3):67S–76S. > Google Scholar
- 19.Schweizer E, Rickels K, Hassman H, Garcia-España F. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry. 1998; 59(4):175–183.
10.4088/JCP.v59n0406 > CrossrefGoogle Scholar - 20.Landen M, Bjorling G, Agren H, A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998; 59(12):664–668.
10.4088/JCP.v59n1204 > CrossrefGoogle Scholar - 21.Trivedi MH, Fava M, Wisniewski SR, STAR*D Team. Medication augmentation after the failure of SSRIs for depression. New Engl J Med. 2006; 354(12):1243–1252.
10.1056/NEJMoa052964 > CrossrefGoogle Scholar - 22.Appelberg BH, Syvalahti EK, Koskinen TE, Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001; 62(6):448–452.
10.4088/JCP.v62n0608 > CrossrefGoogle Scholar - 23.Sramek J, Tansman M, Suri A, Efficacy of buspirone in generalized anxiety disorder with co-existing mild depression symptoms. J Clin Psychiatry. 1996; 57(7):287–291. > Google Scholar
- 24.Sadock BJ, Sadock VA. Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2009. > Google Scholar
- 25.Newton RE, Casten GP, Alms DR, Benes CO, Marunycz JD. The side effect profile of buspirone in comparison to active controls and placebo. J Clin Psychiatry. 1982; 43:12(Pt 2):100–102. > Google Scholar
- 26.Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K. Gepirone extended release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry. 2008; 69(4):571–577.
10.4088/JCP.v69n0408 > CrossrefGoogle Scholar - 27.Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J. Relapse prevention with gepirone-ER in outpatients with major depression. J Clin Psychopharmacol. 2005; 25(1):79–84.
10.1097/01.jcp.0000150221.53877.d9 > CrossrefGoogle Scholar - 28.Alpert J, Franznick D, Hollander S, Gepirone extended release treatment of anxious depression: evidence from a retrospective sub-group analysis in patients with major depressive disorder. J Clin Psychiatry. 2004; 65(8):1069–1075.
10.4088/JCP.v65n0807 > CrossrefGoogle Scholar - 29.Robinson DS, Sitsen JM, Gibertini M. A review of the efficacy and tolerability of immediate release and extended release formulations of gepirone. Clin Ther. 2003; 25(6):1618–1633.
10.1016/S0149-2918(03)80159-5 > CrossrefGoogle Scholar - 30.Davari-Ashtiani R, Shahrbabaki ME, Razjouyan K, Amini H, Mazhabdar H. Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. Child Psychiatry Hum Dev. 2010; 41(6):641–648.
10.1007/s10578-010-0193-2 > CrossrefGoogle Scholar - 31.Brahm NC, Fast GA, Brown RC. Buspirone for autistic disorder in a woman with an intellectual disability. Ann Pharmacother. 2008; 42(1):131–137. > Google Scholar
- 32.Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine monodependence management in outpatient settings. Cochrane Database Syst Rev. 2006; 19;3:CD005194. > Google Scholar
- 33.Jaffee MS, Bostwick JM. Buspirone as an antidote to venlafaxine-induced bruxism. Psychosomatics. 2000; 41(6):535–536.
10.1176/appi.psy.41.6.535 > CrossrefGoogle Scholar - 34.Kuloglu M, Ekinci O, Caykoylu A. Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone. J Psychopharmacol. 2010; 24(4):627–628.
10.1177/0269881109102612 > CrossrefGoogle Scholar - 35.Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in four cases. J Clin Psychiatry. 1999; 60(12):857–860.
10.4088/JCP.v60n1209 > CrossrefGoogle Scholar - 36.McRae-Clark AL, Carter RE, Killeen TK, A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009; 105(1–2):132–138.
10.1016/j.drugalcdep.2009.06.022 > CrossrefGoogle Scholar - 37.Lenhardt R, Orhan-Sungur M, Komatsu R, Suppression of shivering during hypothermia using a novel drug combination in healthy volunteers. Anesthesiology. 2009; 111(1):110–115.
10.1097/ALN.0b013e3181a979a3 > CrossrefGoogle Scholar - 38.Guluma KZ, Hemmen TM, Olsen SE, Rapp KS, Lyden PD. A trial of therapeutic hypothermia via endovascular approach in awake patients with acute ischemic stroke: methodology. Acad Emerg Med. 2006; 13(8):820–827.
10.1111/j.1553-2712.2006.tb01731.x > CrossrefGoogle Scholar - 39.Grady TA, Pigott TA, L’Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993; 150(5):819–821. > Google Scholar
- 40.Jenike MA, Baer L, Butolph L. Buspione augmentation of fluoxetine in patents with obsessive-compulsive disorder. J Clin Psychiatry. 1991; 52(1):13–14. > Google Scholar
- 41.McDougle CJ, Goodman WK, Leckman JF, Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry. 1993; 150(4):647–649. > Google Scholar
- 42.Buydens-Branchey L, Branchey M, Reel-Brander C. Efficacy of buspirone in the treatment of opioid withdrawal. J Clin Psychopharmacol. 2005; 25(3):230–236.
10.1097/01.jcp.0000162804.38829.97 > CrossrefGoogle Scholar - 43.Rose JS, Branchey M, Wallach L, Buydens-Branchey L. Effects of buspirone in withdrawal from opiates. Am J Addict. 2003; 12(3):253–259. > Google Scholar
- 44.Sheehan DV, Raj AB, Sheehan KH, Is buspirone effective or panic disorder?J Clin Psychopharmcol. 1990; 10(1):3–11.
10.1097/00004714-199002000-00002 > CrossrefGoogle Scholar - 45.Pohl R, Balen R, Yeragani VK. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology. 1989; 22(Suppl 1):60–67.
10.1159/000284627 > CrossrefGoogle Scholar - 46.Landen M, Eriksson O, Sundblad C, Andersch B, Naessén T, Eriksson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone, and placebo. Psychopharmacology (Berl). 2001; 155(3):292–298.
10.1007/s002130100718 > CrossrefGoogle Scholar - 47.Schneier FR, Saoud JB, Campcas R, Buspirone in social phobia. J Clin Psychopharmacol. 1993; 13(4):251–256.
10.1097/00004714-199308000-00004 > CrossrefGoogle Scholar - 48.van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry. 1997; 58(4):164–168.
10.4088/JCP.v58n0405 > CrossrefGoogle Scholar - 49.Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999; 19(3):268–271.
10.1097/00004714-199906000-00012 > CrossrefGoogle Scholar - 50.Michelson D, Bancroft J, Targum S, Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacological intervention. Am J Psychiatry. 2000; 157(2):239–243.
10.1176/appi.ajp.157.2.239 > CrossrefGoogle Scholar - 51.Robinson MD, Pettice YL, Smith WA, Cederstrom EA, Sutherland DE, Davis H. Buspirone effect on tobacco withdrawal symptoms: a randomized placebo-controlled trial. J Am Board Fam Pract. 1992; 5(1):1–9. > Google Scholar
- 52.West R, Hajek P, McNeill A. Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic. Psychopharmacology (Berl). 1991; 104(1):91–96.
10.1007/BF02244560 > CrossrefGoogle Scholar
